Global ENT Disorder Treatment Market 2017-2021
About ENT Disorder Treatment
ENT also known as otolaryngology, is an area of medicine that deals with disorders of ear, nose, and throat. Dysfunction of these body parts can affect quality of life and in certain cases may even lead to medical emergency. The market encompasses drugs that are used for the treatment of the ENT disorder. It mainly considers the various drug class used for the treatment of numerous symptoms of the disease. The major ENT disorders included in the report are rhinitis, sinusitis, otitis media, and tonsillitis.
Technavio’s analysts forecast the global ENT disorder treatment market to grow at a CAGR of 2.17% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global ENT disorder treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales from both branded and generic drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global ENT Disorder Treatment Market 2017-2021
Technavio recognizes the following companies as the key players in the global ENT disorder treatment market: ALK, GSK, Novartis, and Sanofi.
Other Prominent Vendors in the market are: Allergan, AstraZeneca, Dr. Reddy's Laboratories, Lupin, Merck, Mylan, Otonomy, Pfizer, Sun Pharma, and Teva Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “One trend in market is increase in research on allergic disorders. Allergic diseases such as rhinitis, if not managed properly, have chances of developing into organizations around the world are working to have a better understanding of the pathogenesis of allergic diseases. For instance, The Australasian Society of Clinical Immunology and Allergy, Allergy and Anaphylaxis Australia, and the European Academy of Allergy and Clinical Immunology are working for a better understanding of allergic diseases.”
According to the report, one driver in market is deteriorating environmental conditions. Deteriorating environmental conditions is one of the major reasons for the rising prevalence of ENT disorders such as rhinitis. For instance, perennial allergic rhinitis can prevail around the year and is often the result of sensitivity to mold on wallpaper, pet hair, carpeting, houseplants, and upholstery. Also, congested living conditions and high pollution levels are known to be some of the primary factors leading to sinusitis. Studies have suggested that allergic rhinitis can be aggravated by certain polluting agents such as automobile engine emission. The problem is more severe in urban areas specifically in developing countries like India and China. It is estimated that more than three-fourth of the urban population is exposed to the air quality that exceeds the WHO limits.
Further, the report states that one challenges in market is growing cases of anti-bacterial resistance. Antimicrobial resistance is one of the major public health challenges faced globally, and has been accelerated by the overuse of antibiotics across the globe. Overprescribing antibiotics is a common problem in primary care, where most of the infections are caused by viruses. It is estimated that general practitioners prescribe 90% of the total antibiotic prescriptions, where respiratory tract infections and respiratory disorders are the major causes of prescription. Per the data provided by the CDC more than two million people worldwide, each year, are identified as being antibiotic resistant. Antibiotic resistance adds avoidable and considerable cost on the already overburdened healthcare system. As per the CDC, antibiotic resistance is estimated to have an economic burden of $55 billion on the US per year. The CDC indicates that about 235 million antibiotic doses are administered per year, of these 20%-50% are not needed.
ALK, GSK, Novartis, Sanofi, Allergan, AstraZeneca, Dr. Reddy's Laboratories, Lupin, Merck, Mylan, Otonomy, Pfizer, Sun Pharma, and Teva Pharmaceuticals.